Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Novo Nordisk's Karsten Munk Knudsen is targeting 800 million obese people globally.

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs, she had the briefest of ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Americans are split on using weight loss drugs such as Ozempic and Wegovy to treat obesity or weight-related conditions, ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

New poll shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs if they are ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

New research uncovers hidden risks and surprising benefits of weight loss drugs like Ozempic, reshaping how we see these ...